Startsida
Hjälp
Sök i LIBRIS databas

     

 

Sökning: onr:z6t2h1b3w1bhgf13 > Lowering LDL choles...

Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation [Elektronisk resurs]

Storey, Benjamin C (författare)
Staplin, Natalie (författare)
Haynes, Richard (författare)
Reith, Christina (författare)
Emberson, Jonathan (författare)
Herrington, William G (författare)
Wheeler, David C (författare)
Walker, Robert (författare)
Fellström, Bengt, 1947- (författare)
Wanner, Christoph (författare)
Landray, Martin J (författare)
Baigent, Colin (författare)
Uppsala universitet Medicinska och farmaceutiska vetenskapsområdet (utgivare)
Publicerad: 2018
Engelska.
Ingår i: Kidney International. - 0085-2538. ; 93:4, 1000-1007
Läs hela texten
Läs hela texten
Läs hela texten
  • E-artikel/E-kapitel
Sammanfattning Ämnesord
Stäng  
  • Markers of inflammation, including plasma C-reactive protein (CRP), are associated with an increased risk of cardiovascular disease, and it has been suggested that this association is causal. However, the relationship between inflammation and cardiovascular disease has not been extensively studied in patients with chronic kidney disease. To evaluate this, we used data from the Study of Heart and Renal Protection (SHARP) to assess associations between circulating CRP and LDL cholesterol levels and the risk of vascular and non-vascular outcomes. Major vascular events were defined as nonfatal myocardial infarction, cardiac death, stroke or arterial revascularization, with an expanded outcome of vascular events of any type. Higher baseline CRP was associated with an increased risk of major vascular events (hazard ratio per 3x increase 1.28; 95% confidence interval 1.19-1.38). Higher baseline LDL cholesterol was also associated with an increased risk of major vascular events (hazard ratio per 0.6 mmol/L higher LDL cholesterol; 1.14, 1.06-1.22). Higher baseline CRP was associated with an increased risk of a range of non-vascular events (1.16, 1.12-1.21), but there was a weak inverse association between baseline LDL cholesterol and non-vascular events (0.96, 0.92-0.99). The efficacy of lowering LDL cholesterol with simvastatin/ezetimibe on major vascular events, in the randomized comparison, was similar irrespective of CRP concentration at baseline. Thus, decisions to offer statin-based therapy to patients with chronic kidney disease should continue to be guided by their absolute risk of atherosclerotic events. Estimation of such risk may include plasma biomarkers of inflammation, but there is no evidence that the relative beneficial effects of reducing LDL cholesterol depends on plasma CRP concentration. 

Ämnesord

Medical and Health Sciences  (hsv)
Medicin och hälsovetenskap  (hsv)

Indexterm och SAB-rubrik

C-reactive protein
LDL cholesterol
inflammation
randomized trials
vascular disease
Inställningar Hjälp

Beståndsinformation saknas

Om LIBRIS
Sekretess
Hjälp
Fel i posten?
Kontakt
Teknik och format
Sök utifrån
Sökrutor
Plug-ins
Bookmarklet
Anpassa
Textstorlek
Kontrast
Vyer
LIBRIS söktjänster
SwePub
Uppsök

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

Copyright © LIBRIS - Nationella bibliotekssystem

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy